New Feature: See every earnings report in one clear view

Rein Therapeutics

Contributing Author

Recent Articles by Rein Therapeutics

10 hours	Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update RNTX GlobeNewswire
Aug-04	Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications RNTX GlobeNewswire
Jul-21	Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries RNTX +6.02% GlobeNewswire
Jun-11	Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom RNTX GlobeNewswire
May-18	Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option RNTX GlobeNewswire
Apr-30	Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock RNTX -23.99% GlobeNewswire
Apr-29	Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX -12.07% GlobeNewswire
Mar-03	Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Jan-20	Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Nov-06	Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF RNTX GlobeNewswire
Nov-03	Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX +11.82% GlobeNewswire
Oct-09	Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Sep-17	Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Aug-19	Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Aug-14	Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 RNTX GlobeNewswire
Jul-30	Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing RNTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)